Macquarie Group Ltd. Acquires New Stake in Loxo Oncology, Inc. (LOXO)

Macquarie Group Ltd. acquired a new stake in shares of Loxo Oncology, Inc. (NASDAQ:LOXO) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 51,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,090,000. Macquarie Group Ltd. owned about 0.17% of Loxo Oncology as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Legal & General Group Plc lifted its position in shares of Loxo Oncology by 8.4% during the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 284 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Loxo Oncology by 4,388.0% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 2,194 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Loxo Oncology during the 2nd quarter valued at $228,000. Marshall Wace LLP acquired a new stake in shares of Loxo Oncology during the 2nd quarter valued at $233,000. Finally, Jasper Ridge Partners L.P. acquired a new stake in shares of Loxo Oncology during the 2nd quarter valued at $277,000.

Shares of Loxo Oncology, Inc. (LOXO) opened at 85.03 on Friday. The firm’s market capitalization is $2.54 billion. Loxo Oncology, Inc. has a 52 week low of $17.14 and a 52 week high of $95.92. The firm’s 50-day moving average is $86.39 and its 200 day moving average is $68.85.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.15). During the same quarter in the previous year, the company earned ($0.77) EPS. Equities research analysts forecast that Loxo Oncology, Inc. will post ($4.49) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Macquarie Group Ltd. Acquires New Stake in Loxo Oncology, Inc. (LOXO)” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://sportsperspectives.com/2017/10/20/macquarie-group-ltd-acquires-new-stake-in-loxo-oncology-inc-loxo.html.

A number of equities research analysts have recently commented on LOXO shares. BidaskClub downgraded Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Sunday, July 16th. BTIG Research reiterated a “buy” rating and set a $75.00 price objective on shares of Loxo Oncology in a research report on Thursday, August 3rd. Stifel Nicolaus reiterated a “buy” rating and set a $71.00 price objective on shares of Loxo Oncology in a research report on Thursday, August 3rd. Zacks Investment Research upgraded Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price objective for the company in a research report on Wednesday, August 9th. Finally, Ifs Securities reiterated an “outperform” rating on shares of Loxo Oncology in a research report on Tuesday, August 8th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $76.31.

In other news, CEO Joshua H. Bilenker sold 15,000 shares of Loxo Oncology stock in a transaction on Tuesday, August 15th. The shares were sold at an average price of $73.56, for a total transaction of $1,103,400.00. Following the transaction, the chief executive officer now directly owns 196,207 shares of the company’s stock, valued at $14,432,986.92. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Jennifer Burstein sold 1,700 shares of Loxo Oncology stock in a transaction on Monday, August 14th. The stock was sold at an average price of $73.73, for a total transaction of $125,341.00. Following the transaction, the vice president now directly owns 1,700 shares in the company, valued at $125,341. The disclosure for this sale can be found here. Over the last three months, insiders have sold 89,896 shares of company stock worth $7,315,562. Insiders own 44.40% of the company’s stock.

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply